NCT03270709 is a Phase 1 clinical trial of Vitamin D3 450,000 IU orally in HIV/AIDS, sponsored by Emory University.

Who is sponsoring NCT03270709?

NCT03270709 is sponsored by Emory University.

What drugs are being tested in NCT03270709?

Interventions in NCT03270709: Vitamin D3 450,000 IU orally.

What condition does NCT03270709 study?

NCT03270709 studies HIV/AIDS, Vitamin D Deficiency, Smoker Lung.

Is NCT03270709 still recruiting?

NCT03270709 is currently terminated. Last updated 21 April 2021.

Last reviewed 2021-04-21 · How we verify

NCT03270709

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of High-Dose Vitamin D3 in Smokers and Non-Smokers With and Without HIV

Terminated Phase 1 Last updated 21 April 2021

What this trial tests

Phase 1 trial testing Vitamin D3 450,000 IU orally in HIV/AIDS in 7 participants. Terminated before completion.

Timeline

11 April 2018

Primary endpoint
15 October 2018

15 October 2018

Quick facts

Lead sponsor	Emory University
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	7
Start date	11 April 2018
Primary completion	15 October 2018
Estimated completion	15 October 2018
Sites	2 locations across United States

Drugs / interventions tested

Vitamin D3 450,000 IU orally — full drug profile →

Conditions studied

HIV/AIDS — all drugs for HIV/AIDS →
Vitamin D Deficiency — all drugs for Vitamin D Deficiency →
Smoker Lung — all drugs for Smoker Lung →

Sponsor

Emory University

Who can join

18 and older, any sex, with HIV/AIDS or Vitamin D Deficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Supplementation with vitamin D improves HIV+ macrophages phagocytosis in vitro. There is evidence to suggest that administering vitamin D can in fact improve immune function in individuals. The study will evaluate the impact of high dose vitamin D in HIV+ smokers' and HIV- smokers' in vivo. The primary goal is to improve innate immune host response to infection in patients already at high risk by virtue of HIV and smoking status.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Vitamin D-Cathelicidin Axis: at the Crossroads between Protective Immunity and Pathological Inflammation during Infection.
Chung C, Silwal P, Kim I, Modlin RL, et al · · 2020 · cited 91× · PMID 32395364 · DOI 10.4110/in.2020.20.e12
Cathelicidins: Opportunities and Challenges in Skin Therapeutics and Clinical Translation.
Dzurová L, Holásková E, Pospíšilová H, Schneider Rauber G, et al · · 2024 · cited 8× · PMID 39858288 · DOI 10.3390/antibiotics14010001

Verify or expand the search:

Other recruiting trials for HIV/AIDS

Currently open trials in the same condition.

NCT06741618 — MyPEEPS Mobile Plus: A Multi-Level HIV Prevention Intervention for Young MSM · NA · recruiting
NCT07298785 — Peer-led Dynamic Choice HIV Prevention for Women: The Peer-led DCP Pilot Study · NA · recruiting
NCT07072481 — Sustaining Innovative Tools to Expand Youth-Friendly HIV Self-Testing · NA · recruiting
NCT07064785 — Video-Intervention to Inspire Treatment Adherence for Life for Adolescents · NA · recruiting
NCT07074899 — Evaluation of a Multi-Component Intervention to Support HIV Testing and Linkage to Services Among MSM in Peru · NA · active not recruiting

Other Emory University trials

Trials by the same sponsor.

NCT06143345 — HIIT in Isolated IFG: A Proof-of-Concept Study · NA · withdrawn
NCT07189819 — Innovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait · NA · not yet recruiting
NCT06451055 — Low-calorie Diet in Isolated Impaired Fasting Glucose · NA · not yet recruiting
NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I · Phase 2 · recruiting
NCT06708351 — Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03270709 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Emory University
Last refreshed: 21 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03270709.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing